These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27740994)

  • 1. Potential Safety Issues Related to the Use of Gadolinium-based Contrast Agents.
    Pinter NK; Klein JP; Mechtler LL
    Continuum (Minneap Minn); 2016 Oct; 22(5, Neuroimaging):1678-1684. PubMed ID: 27740994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium deposition in the brain: summary of evidence and recommendations.
    Gulani V; Calamante F; Shellock FG; Kanal E; Reeder SB;
    Lancet Neurol; 2017 Jul; 16(7):564-570. PubMed ID: 28653648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are some agents less likely to deposit gadolinium in the brain?
    Radbruch A
    Magn Reson Imaging; 2016 Dec; 34(10):1351-1354. PubMed ID: 27629022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium tissue deposition in brain and bone.
    Murata N; Murata K; Gonzalez-Cuyar LF; Maravilla KR
    Magn Reson Imaging; 2016 Dec; 34(10):1359-1365. PubMed ID: 27720805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium deposition in the brain.
    Kanda T; Nakai Y; Oba H; Toyoda K; Kitajima K; Furui S
    Magn Reson Imaging; 2016 Dec; 34(10):1346-1350. PubMed ID: 27613998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it safe to use gadolinium-based contrast agents in MRI?
    Pullicino R; Das K
    J R Coll Physicians Edinb; 2017 Sep; 47(3):243-246. PubMed ID: 29465099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
    Layne KA; Dargan PI; Archer JRH; Wood DM
    Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium retention in the body: what we know and what we can do.
    Tedeschi E; Caranci F; Giordano F; Angelini V; Cocozza S; Brunetti A
    Radiol Med; 2017 Aug; 122(8):589-600. PubMed ID: 28361260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists.
    Costa AF; van der Pol CB; Maralani PJ; McInnes MDF; Shewchuk JR; Verma R; Hurrell C; Schieda N
    Can Assoc Radiol J; 2018 Nov; 69(4):373-382. PubMed ID: 30249408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium Retention and Toxicity-An Update.
    Ramalho M; Ramalho J; Burke LM; Semelka RC
    Adv Chronic Kidney Dis; 2017 May; 24(3):138-146. PubMed ID: 28501075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of the Current Evidence on Gadolinium Deposition in the Brain.
    Pullicino R; Radon M; Biswas S; Bhojak M; Das K
    Clin Neuroradiol; 2018 Jun; 28(2):159-169. PubMed ID: 29523896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood-brain barrier.
    Prybylski JP; Maxwell E; Coste Sanchez C; Jay M
    Magn Reson Imaging; 2016 Dec; 34(10):1366-1372. PubMed ID: 27580521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.
    Blumfield E; Swenson DW; Iyer RS; Stanescu AL
    Pediatr Radiol; 2019 Apr; 49(4):448-457. PubMed ID: 30923876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?
    Layne KA; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2020 Mar; 58(3):151-160. PubMed ID: 31663374
    [No Abstract]   [Full Text] [Related]  

  • 15. Gadolinium-based contrast agents: did we miss something in the last 25 years?
    Beomonte Zobel B; Quattrocchi CC; Errante Y; Grasso RF
    Radiol Med; 2016 Jun; 121(6):478-81. PubMed ID: 26706453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of gadolinium deposition in the brain tissue of pediatric and adult congenital heart disease patients after contrast enhanced cardiovascular magnetic resonance.
    Zaki N; Parra D; Wells Q; Chew JD; George-Durrett K; Pruthi S; Soslow J
    J Cardiovasc Magn Reson; 2020 Dec; 22(1):82. PubMed ID: 33267835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
    Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
    Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium contrast agents - are they really safe?
    Malikova H; Holesta M
    J Vasc Access; 2017 Mar; 18(Suppl. 2):1-7. PubMed ID: 28362042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technical aspects of MRI signal change quantification after gadolinium-based contrast agents' administration.
    Ramalho J; Ramalho M; AlObaidy M; Semelka RC
    Magn Reson Imaging; 2016 Dec; 34(10):1355-1358. PubMed ID: 27693606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan).
    Runge VM
    Invest Radiol; 2018 Oct; 53(10):571-578. PubMed ID: 30130320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.